Innovative developer of therapies targeting inflammation accelerates growth with clinivation’s clinical, regulatory, design, and quality assurance solutions.
Framingham, MA, January 12, 2007 – clinivation, Inc. announced today that Vasogen, Inc. (NASDAQ CM: VSGN) has selected clinivation’s clinical, regulatory, design and quality assurance solutions.
“Vasogen is focused on developing treatments targeting chronic inflammation underlying cardiovascular and neurological disease,” remarked Joseph Kozikowski, M.D., clinivation’s Founder, Chairman, and Chief Executive Officer. “We are pleased that Vasogen’s senior management has selected clinivation to assist in the restructuring of Vasogen’s Celacade program,” he continued.
During the 2006 fiscal year, Vasogen completed a 2,408-patient double blind, placebo-controlled advanced chronic heart failure clinical assessment of immune modulation therapy (ACCLAIM) trial. This trial assessed the impact of Vasogen’s lead product, Celacade, on reducing the risk of mortality and morbidity in patients with chronic heart failure (HF). On June 26, 2006, Vasogen announced the initial results from the ACCLAIM trial. The Celacade technology is designed to be integrated at multiple points of care, including outpatient hospital clinics and cardiology practices.
Clinivation’s rapidly-implementable quality systems infrastructure solutions are pre-configured, matched to specific client needs, and designed to scale with product history and organization growth. Clinivation’s design assurance solutions integrate and leverage quality systems, regulatory process, and design engineering, enabling customers to launch better medical systems faster.
About Vasogen, Inc.
Vasogen, Inc. is engaged in the research and commercial development of technologies targeting the chronic inflammation underlying cardiovascular and neurological disease. Apart from the Celacade technology, Vasogen is also developing a new class of drugs for the treatment of neuro-inflammatory disorders. VP025 is the lead product candidate from this class of drugs.
Vasogen has two wholly owned subsidiaries: Vasogen, Corp. and Vasogen Ireland Limited.
For further information, visit www.vasogen.com.